

Kartik R Roy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7073069/publications.pdf>

Version: 2024-02-01

8
papers

130
citations

1684188
5
h-index

1588992
8
g-index

8
all docs

8
docs citations

8
times ranked

216
citing authors

| # | ARTICLE | IF | CITATIONS |
|---|--|-----|-----------|
| 1 | An N-methyladenosine at the transited codon 273 of p53 pre-mRNA promotes the expression of R273H mutant protein and drug resistance of cancer cells. <i>Biochemical Pharmacology</i> , 2019, 160, 134-145. | 4.4 | 74 |
| 2 | Ceramide-Rubusoside Nanomicelles, a Potential Therapeutic Approach to Target Cancers Carrying p53 Missense Mutations. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 564-574. | 4.1 | 15 |
| 3 | Cb3-Src complex in glycosphingolipid-enriched microdomains contributes to the expression of p53 mutant protein and cancer drug resistance via β -catenin-activated RNA methylation. <i>FASEB BioAdvances</i> , 2020, 2, 653-667. | 2.4 | 12 |
| 4 | Incorporation of Fluorescence Ceramide-Based HPLC Assay for Rapidly and Efficiently Assessing Glucosylceramide Synthase In Vivo. <i>Scientific Reports</i> , 2017, 7, 2976. | 3.3 | 9 |
| 5 | Rubusoside-assisted solubilization of poorly soluble C6-Ceramide for a pilot pharmacokinetic study. <i>Prostaglandins and Other Lipid Mediators</i> , 2020, 146, 106402. | 1.9 | 8 |
| 6 | Recruitment of MLL1 complex is essential for SETBP1 to induce myeloid transformation. <i>IScience</i> , 2022, 25, 103679. | 4.1 | 6 |
| 7 | p53 missense mutant G242A subverts natural killer cells in sheltering mouse breast cancer cells against immune rejection. <i>Experimental Cell Research</i> , 2022, 417, 113210. | 2.6 | 4 |
| 8 | Fluorescence HPLC Analysis of the in-vivo Activity of Glucosylceramide Synthase. <i>Bio-protocol</i> , 2019, 9, e3269. | 0.4 | 2 |